FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations.
We investigated possible explanations for the common occurrence of perivenular lesions in liver allografts of patients on FK506 within a few weeks to several months after OLT. Hematoxylin and eosin-stained sections of pre- and postperfusion biopsy specimens and day 7 post-transplant protocol biopsy specimens from 31 patients, randomly assigned to either FK506 or CsA as primary immunosuppressive agent, were reviewed, and immunohistochemical stains for HLA-DR antigen and S-100 protein were performed by the avidin-biotin peroxidase complex method. The histologic features of cellular rejection in the portal tracts of day 7 posttransplant allograft biopsy specimens from patients on FK506 were milder than those from patients on CsA. Immunohistochemical stains for HLA-DR showed intense positivity in a variety of cell types in day 7 posttransplant specimens from both groups, including sinusoidal-lining cells, bile duct epithelial cells, vascular endothelial cells, inflammatory cells, and occasional injured hepatocytes. Although diffuse lobular staining was seen in the majority of cases in both groups, either with or without rejection, liver biopsy specimens from patients on FK506 showed concentration of positively stained cells in perivenular regions more often, and at a lower overall histologic grade of rejection, than specimens from patients on CsA. There were no differences in the number and distribution of S-100 protein-positive dendritic APC between biopsy specimens from FK506 versus CsA-treated patients, or between specimens with and without cellular rejection in either group. It is suggested that the development of perivenular injury, which is seen frequently in allograft biopsy specimens from patients on FK506 obtained at various intervals after transplantation, may be related to drug toxicity rather than to the process of allograft rejection.
Hytiroglou
P
P
Lillian and Henry M. Stratton, Hans Popper Department of Pathology, Mount Sinai School of Medicine, New York, New York 10029.
Lee
R
R
Sharma
K
K
Theise
N D
ND
Schwartz
M
M
Miller
C
C
Thung
S N
SN
D016572:Cyclosporine / Q000009:adverse effects*; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D008099:Liver / Q000187:drug effects / Q000293:injuries / Q000473:pathology; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology* / Q000473:pathology*; D009418:S100 Proteins / Q000378:metabolism; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors
D006684:HLA-DR Antigens; D009418:S100 Proteins; D016572:Cyclosporine; D016559:Tacrolimus